More early data manipulation issues tied to Novartis blockbuster as Nature retracts paper
Novartis’ blockbuster gene therapy Zolgensma has proven to be a major success story as a spinal muscular atrophy treatment, helping children who might not otherwise …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.